A Phase I Study of XL119 (Rebeccamycin Analogue) in Combination With Oxaliplatin in Patients With Refractory Solid Tumors

Inclusion Criteria:

- Patients must have a histologically confirmed solid tumor that is not amenable to
conventional surgical, radiation therapy or chemotherapy treatment programs

- Prior chemotherapy and/or radiation are allowed; at least 4 weeks must have elapsed
since prior large-field radiation therapy; patients must have been off previous
anti-cancer therapy for at least 3 weeks (6 weeks for mitomycin-C and nitrosoureas);
and recovered from all treatment related toxicity

- ECOG performance status =< 2 (Karnofsky >60%)

- Life expectancy of at least 12 weeks

- Absolute neutrophil count >= 1,500/ul

- Platelets >= 100,000/ul

- Hemoglobin >= 9.0 g/dl

- Total bilirubin =< 1.5 mg/dl

- AST(SGOT) < 2.5 X institutional upper limit of normal

- Creatinine < 1.5 mg/dl OR creatinine clearance >= 60 mL/min/1.73 m^2 for patients
with creatinine levels above institutional normal

- Women of child-bearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control; abstinence) prior to study entry and
for the duration of study participation; should a woman become pregnant or suspect
she is pregnant while participating in this study, she should inform her treating
physician immediately

- Ability to understand and the willingness to sign a written informed consent document

- All patients should have a central line placed for XL119 administration

Exclusion Criteria:

- Patients may not be receiving any other investigational agents or have received other
investigational agents for at least 4 weeks

- Patients with known brain metastases should be excluded from this clinical trial

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- Pregnant and lactating women are excluded from this study

- HIV-positive patients receiving combination anti-retroviral therapy are excluded from
the study

- NYHA classification III or IV heart disease